WOMEN'S HEALTH AGENDA

女性健康议程

• 批准号: 6099182
• 负责人: Lawrence JOSEPH WHEAT
• 金额: $ 14.14万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-01-01 至 1999-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6099182
• 关键词: 2'3' dideoxyinosine; AIDS; AIDS therapy; HIV infections; antiAIDS agent; biomarker; candidiasis; cervix neoplasms; clinical research; clinical trial phase I; comorbidity; cooperative study; drug screening /evaluation; female; human immunodeficiency virus 1; human pregnant subject; human subject; human therapy evaluation; immunotherapy; mucosal immunity; opportunistic infections; pharmacokinetics; reproductive system disorder; women's health

The clinical core of the Indiana ACTU has the following objectives: (1) Enrollment and retention of HIV infected individuals into high priority protocols as part of the overall ACTG mission. A necessary corallary of this objective is production of high quality data which can be accrued only if the subjects are followed carefully and retained in trials for the appropriate length of time. (2) Continued evaluation of patients already enrolled in ACTG clinical trials. (3) Continued creative input into the ACTG in areas where investigators at Indiana have expertise. During the previous funding period, this has been primarily in the area of opportunistic infections with emphasis on disseminated histoplasmosis, which is endemic in Indianapolis and Pneumocystis carinii pneumonia where we have the opportunity to take advantage of tissue culture and animal model evaluation of anti- pneumocystis compounds currently being conducted on our campus. (4) Expansion of our capabilities to include evaluation of therapy for the opportunistic malignancies and dementia which accompany HIV infection. (5) Through an aggressive outreach program which includes the addition of a subunit at Methodist Hospital in Indianapolis and a possible subunit in Gary, Indiana, increased enrollment in ACTG protocols of previously under- represented populations, i.e., women, persons of color, and IVDUs. In order to accomplish this objective, the Indiana ACTU has developed extensive ties with community groups in Central Indiana and is in the process of developing similar ties in northwestern Indiana. One of our major objectives is inclusion of more minority physicians as active participants in the conduct of our trials.

印第安纳州ACTU的临床核心目标如下： (1)将艾滋病毒感染者纳入高度优先项目并使其继续留在项目中 作为整个ACTG使命的一部分。 一个必要的珊瑚 这一目标是产生高质量的数据， 如果受试者被仔细随访并保留在试验中， 适当的时间长度。 (2)继续评价已入组ACTG临床研究的患者 审判 (3)在调查人员在 印第安纳州有专家。 在上一个供资期间， 主要是在机会性感染领域， 播散性组织胞浆菌病是印第安纳波利斯的地方病， 卡氏肺孢子虫肺炎我们有机会采取 组织培养的优势及抗- 肺孢子虫化合物目前正在进行我们的校园。 (4)扩大我们的能力，以包括评估治疗 机会性恶性肿瘤和痴呆症，伴随着艾滋病毒感染。 (5)通过积极的推广计划，其中包括增加 印第安纳波利斯卫理公会医院的一个亚单位， 印第安纳州的加里增加了ACTG方案的入组人数， 代表人口，即，女性、有色人种和静脉注射吸毒者。 在 为了实现这一目标，印第安纳州ACTU开发了 与印第安纳州中部的社区团体有着广泛的联系， 在印第安纳州西北部发展类似关系的过程。 我们的一 主要目标是纳入更多的少数民族医生作为积极的 参与我们的审判。